Awani Review

Complete News World

COVID-19: Valneva hopes its vaccine will be 'more than 80%' effective

COVID-19: Valneva hopes its vaccine will be ‘more than 80%’ effective

Paris | The French-Austrian laboratory Valneva, whose trials of its candidate vaccine against COVID-19 have reached an advanced stage, show “efficiency greater than 80%”, announced on Tuesday its director general, Frank Grimaud.

“On the basis of (…) Phase I and Phase II trials, we hope to obtain a vaccine that is more than 80% effective. This must be demonstrated in a Phase III trial, “which aims to establish the true efficacy of the treatment before potential marketing and which is still in progress As stated by Mr. Grimaud on BFM Business.

The efficacy will therefore be lower than that of mRNA vaccines, such as those made by Pfizer/BioNTech or Moderna, which is about 95%. But it will be higher than the AstraZeneca and Johnson and Johnson vaccines, which work by viral vectors and range between 60 and 70%.

Valneva uses an inactivated virus vaccine, a more traditional RNA technology, which is used especially in influenza vaccines every year, explained Mr. Grimaud.

“There is a whole range of factors to get a good combination in a vaccine between its efficacy, its harmlessness, its protection period, the duration between the first two doses and the need for a booster…” Frank Grimaud defended.

The lab submitted its request for permission to British health authorities on Monday. The UK has already ordered 100 million doses for the 2021-2022 period, while discussions with the EU are “still ongoing”, according to Mr Grimaud.

Valneva’s CEO believes that fighting COVID-19 will likely require “regular vaccination” in the coming years. He believes that “we will also have to vaccinate teenagers and children, and a vaccine like ours, with its safety profile, may be of interest.”

See also  Elon Musk's satellite internet targets global coverage in September

It also targets “a section of the population that is more reluctant about new vaccine technologies” as well as in countries where access to vaccines remains difficult.